Project Grant R43AI186801
Award Date 8/14/26
Completion Date 7/31/28
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded $306,810 to Capture Bioscience Inc. on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for development and validation of a high-throughput autoimmune antibody detection platform. Capture Bioscience will adapt its Beads by Time-of-Flight (B-TOF) technology to create a comprehensive autoimmunity panel capable of simultaneously...
- Aumenta Biosciences Inc. received a $578,388 project grant from the National Institute of Allergy and Infectious Diseases within the Department of Health and Human Services to develop a bacterially-derived product to enhance immunity and response to immune checkpoint therapy. The Allergy and Infectious Diseases Research program aims to support biomedical research and training in infectious diseases and related areas. Under this award, Aumenta will determine the maximum tolerated dose and dose...
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop oral first-in-class small-molecule therapeutics targeting a novel immunometabolic pathway for multiple sclerosis treatment. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will conduct Phase I research validating the safety, efficacy, and...
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel oral immunoregulatory therapeutics for Helicobacter pylori–induced bacterial gastritis. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will evaluate the therapeutic efficacy of a host-centered product candidate in regulating local and...
- The National Institute of Allergy and Infectious Diseases awarded Partillion Bioscience Corp $306,865 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanovial-based technologies for accelerated monoclonal antibody discovery and characterization. Partillion will engineer novel nanovial formulations to enable streptavidin-antigen complexes as detection agents, increasing the multiplexing capacity of single-cell antibody screening assays. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of Miami $457,128 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered probiotics that induce oral tolerance to adeno-associated virus (AAV)-delivered broadly neutralizing antibodies (BNAbs) against HIV. The project seeks to address host immune responses—specifically anti-drug antibody (ADA) responses—that limit long-term expression of AAV-delivered...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Hospital $911,271 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms regulating integration of engineered B cells in intestinal immunity and inflammation. The research aims to develop a B cell-based immunotherapy platform for treatment of inflammatory bowel disease and related immune-mediated diseases. The project focuses on long-lived plasma...
- Federal Project Grant Award Summary Protabit LLC received $304,602 in Project Grant funding from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective August 7, 2025, with completion targeted for July 31, 2026, supports the development of high-throughput engineering technologies for bispecific antibodies—therapeutic molecules that combine two different antigen-binding domains. The project...
- The National Institute of Allergy and Infectious Diseases, a division of the Department of Health and Human Services, awarded the University of Florida Division of Sponsored Research $392,142 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanoparticle therapeutics for inflammatory bowel disease. The award funds development of an off-the-shelf therapeutic approach using polysaccharide A (PSA)–derived nanoparticles from commensal...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded $824,278 to Texas Biomedical Research Institute on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R01AI201766. The award funds comparative investigation of bacterial antigen presentation mechanisms in Mycobacterium tuberculosis and Francisella tularensis infections to...